Literature DB >> 23861140

Infection risk after orthopedic surgery in patients with inflammatory rheumatic diseases treated with immunosuppressive drugs.

Catrina B Scherrer1, Anne F Mannion, Diego Kyburz, Markus Vogt, Inès A Kramers-de Quervain.   

Abstract

OBJECTIVE: The influence of specific medications on the risk of postoperative infection in patients with rheumatoid arthritis and other inflammatory rheumatic diseases (IRDs) remains unclear. This retrospective study examined the risk of postoperative infection at the site of surgery in patients treated with immunosuppressive drugs (including biologic agents) undergoing different types of orthopedic surgery.
METHODS: The study included 50,359 cases of orthopedic surgery performed in our hospital between 2000 and 2008. The primary outcome was operation-related infection. IRD patients were compared with those with degenerative or posttraumatic disorders, and in IRD patients, the effect of immunosuppressive medication, specifically tumor necrosis factor α (TNFα) inhibitors and their preoperative management, was examined.
RESULTS: There were 373 operation-related infections (0.8%) of 47,887 cases in the degenerative/posttraumatic group and 49 (2.0%) of 2,472 in the IRD group (higher infection rate in the IRD group; odds ratio [OR] 2.58 [95% confidence interval (95% CI) 1.91-3.48], P < 0.001). In the IRD group, elbow and foot surgery had the highest infection rates. The risk of infection was significantly increased in patients taking multiple conventional disease-modifying antirheumatic drugs (DMARDs; OR 2.49 [95% CI 1.06-5.84], P = 0.036) or TNFα inhibitors (OR 2.54 [95% CI 1.08-5.97], P = 0.032). The risk was especially high (6 [12%] of 49) if the last dose of TNFα inhibitor was given <1 administration interval before surgery.
CONCLUSION: The risk of postoperative infection was elevated in patients with IRDs, especially those taking >1 conventional DMARD or TNFα inhibitors. It may be advisable to consider stopping TNFα inhibitors ≥1 administration interval before surgery, since the risk of postoperative infection appears to be higher if the operation occurs within this period.
Copyright © 2013 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23861140     DOI: 10.1002/acr.22077

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  15 in total

1.  Pre-operative withholding of infliximab and the risk of infections after major surgery in patients with rheumatoid arthritis.

Authors:  Michael M Ward; Abhijit Dasgupta
Journal:  Rheumatology (Oxford)       Date:  2020-12-01       Impact factor: 7.580

2.  Timing of Abatacept Before Elective Arthroplasty and Risk of Postoperative Outcomes.

Authors:  Michael D George; Joshua F Baker; Kevin Winthrop; Evo Alemao; Lang Chen; Sean Connolly; Jesse Y Hsu; Teresa A Simon; Qufei Wu; Fenglong Xie; Shuo Yang; Jeffrey R Curtis
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-07-11       Impact factor: 4.794

Review 3.  Do genetic susceptibility, Toll-like receptors, and pathogen-associated molecular patterns modulate the effects of wear?

Authors:  Edward M Greenfield
Journal:  Clin Orthop Relat Res       Date:  2014-12       Impact factor: 4.176

4.  [Management of prosthetic joint infections].

Authors:  J Holinka; R Windhager
Journal:  Orthopade       Date:  2016-04       Impact factor: 1.087

Review 5.  Optimizing perioperative outcomes for older patients with rheumatoid arthritis undergoing arthroplasty: emphasis on medication management.

Authors:  Susan M Goodman
Journal:  Drugs Aging       Date:  2015-05       Impact factor: 3.923

6.  Perioperative Timing of Infliximab and the Risk of Serious Infection After Elective Hip and Knee Arthroplasty.

Authors:  Michael D George; Joshua F Baker; Jesse Yenchih Hsu; Qufei Wu; Fenglong Xie; Lang Chen; Huifeng Yun; Jeffrey R Curtis
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-11-02       Impact factor: 4.794

7.  Adverse outcomes following hand surgery in patients with rheumatoid arthritis.

Authors:  Victor M Menchaca-Tapia; Elizabeth M Rodríguez; Irazú Contreras-Yáñez; Martin Iglesias-Morales; Virginia Pascual-Ramos
Journal:  Plast Surg (Oakv)       Date:  2016-05-27       Impact factor: 0.947

Review 8.  Management of perioperative tumour necrosis factor α inhibitors in rheumatoid arthritis patients undergoing arthroplasty: a systematic review and meta-analysis.

Authors:  Susan M Goodman; Indu Menon; Paul J Christos; Rie Smethurst; Vivian P Bykerk
Journal:  Rheumatology (Oxford)       Date:  2015-10-07       Impact factor: 7.580

Review 9.  Preoperative Evaluation and Management of Patients Receiving Biologic Therapies.

Authors:  Zahra Rezaieyazdi; Maryam Sahebari; Mandana Khodashahi
Journal:  Arch Bone Jt Surg       Date:  2019-05

10.  Predicting lower limb periprosthetic joint infections: A review of risk factors and their classification.

Authors:  David A George; Lorenzo Drago; Sara Scarponi; Enrico Gallazzi; Fares S Haddad; Carlo L Romano
Journal:  World J Orthop       Date:  2017-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.